Bristol-Myers Squibb: Why I'm Still Bullish

Core Viewpoint - Bristol-Myers Squibb Company (NYSE: BMY) is recommended with a "Buy" rating due to its potential for stock price appreciation despite having high debt levels [1]. Group 1 - The coverage of Bristol-Myers Squibb was initiated in late March 2024 [1]. - The stock is expected to rise, indicating a positive outlook for investors [1]. - The analysis is provided by a chief investment analyst with extensive experience in navigating diverse investment information [1].